Phase II Trial of Presurgical Treatment with Trastuzumab (H) or Lapatinib (Ty) or the Combination of Trastuzumab and Lapatinib (H plus Ty), Followed by Six Cycles of Docetaxel (T) and Carboplatin (C) with Trastuzumab (TCH) or Lapatinib (TCTy) or the Combination of Trastuzumab and Lapatinib (TCHTy) in Patients with HER2+Breast Cancer

被引：1
|
作者：
Callahan, R. D.
Patel, R.
Chan, D.
Allison, M. A.
DiCarlo, B.
Bosserman, L. D.
Kennedy, A.
Zehngebot, L. M.
Miller, J.
Giuliano, A. E.
Spivack, B.
Lin, L-s
Slamon, D. J.
Hurvitz, S. A.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Comprehens Blood & Canc Ctr, Bakersfield, CA USA
[3] Canc Care Associates, Redondo Beach, CA USA
[4] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[5] Cent Coast Med Oncol, Santa Maria, CA USA
[6] Wilshire Oncol Med Grp, Pomona, CA USA
[7] Hematol & Oncol Consultants, Orlando, FL USA
[8] Olive View UCLA Med Ctr, Sylmar, CA 91342 USA
[9] John Wayne Canc Inst, Santa Monica, CA USA
[10] San Antonio Community Hosp, Breast Ctr, Upland, CA USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P1-11-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-12
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+breast cancer (TRIO-US B07)
    Hurvitz, S. A.
    Miller, J. M.
    Dichmann, R.
    Perez, A. T.
    Patel, R.
    Zehngebot, L. M.
    Allen, H.
    Bosserman, L. D.
    DiCarlo, B. A.
    Kennedy, A.
    Giuliano, A.
    Calfa, C. J.
    Molthrop, D. C.
    Mani, A.
    Dering, J.
    Wang, H-J
    Adams, B.
    Martinez, D.
    Chen, W.
    Zoeller, J.
    Brugge, J. S.
    Slamon, D. J.
    CANCER RESEARCH, 2013, 73
  • [2] A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer
    Gerald S. Falchook
    Stacy Moulder
    Aung Naing
    Jennifer J. Wheler
    David S. Hong
    Sarina A. Piha-Paul
    Apostolia M. Tsimberidou
    Siqing Fu
    Ralph Zinner
    Filip Janku
    Yunfang Jiang
    Mei Huang
    Kristin L. Parkhurst
    Razelle Kurzrock
    Investigational New Drugs, 2015, 33 : 177 - 186
  • [3] A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer
    Falchook, Gerald S.
    Moulder, Stacy
    Naing, Aung
    Wheler, Jennifer J.
    Hong, David S.
    Piha-Paul, Sarina A.
    Tsimberidou, Apostolia M.
    Fu, Siqing
    Zinner, Ralph
    Janku, Filip
    Jiang, Yunfang
    Huang, Mei
    Parkhurst, Kristin L.
    Kurzrock, Razelle
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (01) : 177 - 186
  • [4] High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib in the NeoALTTO phase III trial
    Scaltriti, M.
    Nuciforo, P.
    Bradbury, I.
    Sperinde, J.
    Serra, V.
    Parra, J. L.
    Prudkin, L.
    Harbeck, N.
    Pusztai, L.
    Ellis, C.
    Eidtmann, H.
    Arribas, J.
    Piccart, M.
    Baselga, J.
    CANCER RESEARCH, 2013, 73
  • [5] Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
    Ye Yuan
    Xumei Liu
    Yi Cai
    Wenyuan Li
    Systematic Reviews, 11
  • [6] Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+metastatic breast cancer
    Wu, Y.
    Amonkar, M. M.
    Sherrill, B. H.
    O'Shaughnessy, J.
    Ellis, C.
    Baselga, J.
    Blackwell, K. L.
    Burstein, H. J.
    ANNALS OF ONCOLOGY, 2011, 22 (12) : 2582 - 2590
  • [7] Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
    Yuan, Ye
    Liu, Xumei
    Cai, Yi
    Li, Wenyuan
    SYSTEMATIC REVIEWS, 2022, 11 (01)
  • [8] Tolerability of the combination of lapatinib and trastuzumab in older patients with HER2 positive metastatic breast cancer
    O'Connor, Tracey
    Soto-Perez-de-Celis, Enrique
    Blanchard, Suzette
    Chapman, Andrew
    Kimmick, Gretchen
    Muss, Hyman
    Luu, Thehang
    Waisman, James R.
    Li, Daneng
    Mortimer, Joanne
    Yuan, Yuan
    Somlo, George
    Stewart, Daphne
    Katheria, Vani
    Levi, Abrahm
    Hurria, Arti
    CANCER RESEARCH, 2018, 78 (04)
  • [9] Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+breast cancer
    Iwata, H.
    Yamamoto, N.
    Masuda, N.
    Bando, H.
    Kuroi, K.
    Ohno, S.
    Kasai, H.
    Morita, S.
    Sakurai, T.
    Toi, M.
    BREAST, 2015, 24 : S95 - S95
  • [10] A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
    J. Gavilá
    J. De La Haba
    B. Bermejo
    Á. Rodríguez-Lescure
    A. Antón
    E. Ciruelos
    J. Brunet
    E. Muñoz-Couselo
    M. Santisteban
    C. A. Rodríguez Sánchez
    A. Santaballa
    P. Sánchez Rovira
    J. Á. García Sáenz
    M. Ruiz-Borrego
    A. L. Guerrero-Zotano
    M. Huerta
    A. Cotes-Sanchís
    J. Lao Romera
    E. Aguirre
    J. Cortés
    A. Llombart-Cussac
    Clinical and Translational Oncology, 2020, 22 : 420 - 428
12345